The estimated Net Worth of Jeff Himawan is at least $95 Milione dollars as of 26 September 2023. Jeffrey Himawan owns over 32,161 units of Horizon Therapeutics Plc stock worth over $5,180,700 and over the last 18 years he sold HZNP stock worth over $89,300,886. In addition, he makes $521,332 as Independent Director at Horizon Therapeutics Plc.
Sign up
Jeffrey Himawan HZNP stock SEC Form 4 insiders trading
Jeffrey has made over 10 trades of the Horizon Therapeutics Plc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 32,161 units of HZNP stock worth $446,073 on 26 September 2023.
The largest trade he's ever made was selling 3,450,000 units of Horizon Therapeutics Plc stock on 19 November 2014 worth over $41,572,500. On average, Jeffrey trades about 337,606 units every 171 days since 2007. As of 26 September 2023 he still owns at least 44,546 units of Horizon Therapeutics Plc stock.
You can see the complete history of Jeffrey Himawan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jeffrey Himawan biography
Dr. Jeffrey Himawan, Ph.D. is Independent Director of the Company. Dr. Himawan has been a managing director of Essex Woodlands Health Ventures, a venture capital firm, since 2004. Prior to that, he was an adjunct partner at Essex Woodlands from 1999 to 2001, and he was a venture partner from 2001 to 2004. Dr. Himawan co-founded Seed-One Ventures, an early-stage venture capital firm, where he served as a managing director from 1996 to 2001. Dr. Himawan also currently serves on the boards of directors of Catalyst Biosciences, Inc. and MediciNova, Inc., each a public biopharma company, and on the board of directors of NexEos Diagnostics, Inc., a private biotechnology company.
What is the salary of Jeffrey Himawan?
As the Independent Director of Horizon Therapeutics Plc, the total compensation of Jeffrey Himawan at Horizon Therapeutics Plc is $521,332. There are 9 executives at Horizon Therapeutics Plc getting paid more, with Timothy Walbert having the highest compensation of $13,873,200.
How old is Jeffrey Himawan?
Jeffrey Himawan is 55, he's been the Independent Director of Horizon Therapeutics Plc since 2007. There are 10 older and 12 younger executives at Horizon Therapeutics Plc. The oldest executive at Horizon Therapeutics Plc is William Daniel, 67, who is the Independent Director.
What's Jeffrey Himawan's mailing address?
Jeff's mailing address filed with the SEC is C/O HORIZON THERAPEUTICS PLC,, 70 ST. STEPHEN?S GREEN, DUBLIN, L2, D02 E2X4.
Insiders trading at Horizon Therapeutics Plc
Over the last 13 years, insiders at Horizon Therapeutics Plc have traded over $454,905,275 worth of Horizon Therapeutics Plc stock and bought 11,809,010 units worth $58,823,653 . The most active insiders traders include Jeff Himawan, Woodlands Health Ventures F... e Jean Francois Formela. On average, Horizon Therapeutics Plc executives and independent directors trade stock every 13 days with the average trade being worth of $12,248,018. The most recent stock trade was executed by Gino Santini on 2 October 2023, trading 23,092 units of HZNP stock currently worth $351,691.
What does Horizon Therapeutics Plc do?
at horizon therapeutics, we believe science and compassion must work together to transform lives. we are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. for us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.
What does Horizon Therapeutics Plc's logo look like?
Complete history of Jeffrey Himawan stock trades at Catalyst Biosciences Inc, Horizon Therapeutics Plc e Medicinova Inc
Horizon Therapeutics Plc executives and stock owners
Horizon Therapeutics Plc executives and other stock owners filed with the SEC include:
-
Timothy Walbert,
Chairman of the Board, President, Chief Executive Officer -
Timothy P. Walbert,
Chairman, Pres & CEO -
Barry Moze,
Executive Vice President, Chief Administrative Officer -
Paul Hoelscher,
Chief Financial Officer, Executive Vice President -
Vikram Karnani,
Executive Vice President, President - International -
Paul W. Hoelscher,
Exec. VP & CFO -
Andy Pasternak,
Exec. VP & Chief Strategy Officer -
Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D.,
Exec. VP & Chief Medical Officer -
Michael Grey,
Lead Independent Director -
Jeffrey Himawan,
Independent Director -
H. Thomas Watkins,
Independent Director -
James Shannon,
Independent Director -
William Daniel,
Independent Director -
Pascale Witz,
Independent Director -
Susan Mahony,
Independent Director -
Irina Konstantinovsky,
Chief Human Resource Officer, Executive Vice President -
Daniel Camardo,
Executive Vice President, President - U.S. -
Jeffrey Kent,
Senior Vice President, Head of Medical Affairs and Outcomes Research -
Andy Pasternak,
Executive Vice President, Chief Business Officer -
Geoffrey Curtis,
Executive Vice President - Corporate Affairs, Chief Communications Officer -
Tina Ventura,
Senior Vice President, Investor Relations -
Michael DesJardin,
Executive Vice President - Technical Operations and Corporate Quality -
Brian Beeler,
Executive Vice President, General Counsel -
Aaron L. Cox,
Exec. VP of Fin. & CFO -
Jane Gonnerman,
Group VP of Corp. Devel., Chief of Staff & Office of the CEO -
Geoffrey M. Curtis,
Exec. VP of Corp. Affairs & Chief Communications Officer -
Sean M. Clayton J.D.,
Exec. VP & Gen. Counsel -
Timothy Ayers,
Chief Compliance Officer & VP -
Dr. Karin Rosen M.D., Ph.D.,
Exec. VP of R&D and Chief Scientific Officer -
Miles W. McHugh,
Chief Accounting Officer & Sr. VP -
Robert Carey,
EVP & Chief Business Officer -
Jeff Himawan,
Director -
Gino Santini,
Director -
Timothy J. Ackerman,
SVP, Commercial Operations -
Miles W Mc Hugh,
Sr VP & Princ. Acctg Officer -
George P Hampton,
See remarks -
Virinder Nohria,
Director -
Ronald Pauli,
Director -
Vaere Robert J De,
EVP & CFO -
Therapeutics Holdings Llc V...,
10% owner -
Todd N Smith,
SVP, Marketing & Alliance Mgmt -
David Happel,
EVP, Commercial Dev & Strategy -
Eric Mosbrooker,
SVP, Orphan Business Unit -
Shao Lee Lin,
EVP, Head of R&D and CSO -
Jeff Kent,
See remarks -
Jeffrey W Bird,
Director -
Michael Adatto,
Senior VP Sales & Managed Care -
Bio Ventures Ii Lp Quaker,
10% owner -
Venture Fund Vi Lp Atlas Ve...,
-
Peter Johann,
Director -
Jean Francois Formela,
Director -
Venture Fund Vi Lp Atlas Ve...,
-
Woodlands Health Ventures F...,
10% owner -
Louis C Bock,
Director -
Hubert Birner,
Director -
John B Thomas,
EVP, Corporate Strategy and IR -
David George Kelly,
EVP, Company Secretary -
John J Kody,
EVP, Chief Commercial Officer -
Balaji Venkataraman,
-
Aaron Cox,
EVP, Chief Financial Officer -
Jeffrey W Sherman,
EVP and Chief Medical Officer -
Karin Rosen,
EVP, R&D & CSO -
Elizabeth H.Z. Thompson,
EVP, Research & Development -
Sean M. Clayton,
EVP, General Counsel -
Jacopo Leonardi,
Pres., Global Commercial Ops -
Patrick Mc Ilvenny,
Chief Accounting Officer